PharmaRadar360
PharmaRadar360
Intelligence Layer
🇺🇸·1d agoRegulatory

FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause

FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for...

Publisher

F
FDA Drug Approvals

USA

This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.

Read original

In-platform summary, original article off-platform

This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.

Summary excerpt

FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for...

Source route

Continue on fda.gov

Leave the platform to read the original full article on the publisher site.

Source: FDA Drug Approvals

Scope: Regulatory

Open original article
FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause | PharmaRadar360